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Abstract 
Purpose: The purpose of the present study was to explore the biopsychosocial variables affecting 
fatigue in patients with hemoglobinopathies. Methods: 102 patients undergoing transfusion treatment 
from one hospital in Athens, Greece participated in the study. Fatigue was measured with the 
Multidimensional Fatigue Inventory (MFI), quality of life with the Euro5D thermometer as 
self-perceived health and psychological variables with the Depression, Anxiety and Stress Scale (DASS 
21). Statistical analysis was performed with SPSS21. Results: 63 were females (61,4%) and 39 males 
(38,6%). The mean age of the sample was 41.7±9.2 years, while the majority of participants were 
patients with a diagnosis of homozygous β-Thalassemia (81.4%). Multivariate analysis revealed 6 
independent models for each dimension of fatigue, while every one of the five dimensions of MFI as 
well the total score of the inventory, revealed a different model of correlations with mixed variables, 
related with disease complications, adherence to treatment, sex, the self-perceived quality of life, as 
well as the qualitative characteristics of fatigue related with disease complications. Conclusions: 
Fatigue has been identified as a very common symptom in patients with thalassemia with many 
variables affecting it in this population. Our results broadens the evidence regarding fatigue in 
hemoglobinopathies and leads us to the need for distinguishing the etiologies leading to fatigue in 
hemoglobinopathies since it is an important factor affecting HPQoL. Longitudinal studies are needed 
in order to understand the path of fatigue and the factors influencing the condition. 
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1. Introduction 
Haemoglobinopathies (thalassemia and sickle cell disease [SCD]) are the most common hereditary 
diseases in the Greek population. Their current trait incidence in general population is ~8 % and ~1-2%, 
respectively, while during the previous years it had reached up to 15-20%, in certain geographic areas 
(Schizas et al., 1977). According to the new national registry, four thousand thirty-two patients has been 
included in the Greek hemoglobinopathies National registry, while more than half of them has 
thalassaemia major. Compared to the previous report (Voskaridou et al., 2012), a reduction is evident in 
the total number of all hemoglobinopathies, except for hemoglobinopathy “Η” (Voskaridou et al., 2018). 
Based on this report, most patients had low or moderate liver iron concentration (LIC) values, while 
only a non-negligible proportion of them had high LIC. The burden due to heart iron overload was less 
prominent while the major causes of morbidity and mortality are Cardiac- and liver-related 
complications. Although, from 2000 to 2015, researchers observed a decrease in heart-related deaths 
along with an increase in liver-associated fatalities (Voskaridou et al., 2018).  
The introduction of oral iron chelators, including deferiprone in 2000, initially as monotherapy and 
then in combination with deferoxamine, and deferasirox in 2007, has significantly enhanced the 
efficacy of chelation therapy (Tanner et al., 2007), and according to Voskaridou et al. (2018), the 
Hellenic Prevention Program along with the advances in chelation regimens and iron status monitoring 
have resulted in improved patient outcomes.  
Fatigue on the other hand is a nonspecific symptom, because it can be indicative of many causes or 
conditions that includes physiological states such as sleep deprivation or excessive muscular activity, as 
well as medical conditions such as chronic inflammatory conditions, autoimmune illnesses, bacterial or 
viral infections. It can also be indicative of psychiatric disorders such as major depression, anxiety 
disorders, and somatoform disorders (Manu, Lane, & Matthews, 1992), while it is sometimes defined 
as “tiredness”, feeling tired, being fatigued, feeling weak in part of the body, tired or lacking in energy, 
or experiencing “everything as an effort” (Cope, 1992, p. 273). 
Over the last thirty years, fatigue has come to be recognized as a serious symptom of many illnesses 
that can significantly impair a person’s functioning and have a negative impact on quality of life in 
many chronic illnesses, including after cancer treatment (Bartsch, Weis, & Moser, 2003; Irvine, Vincent, 
Graydon, Bubela, & Thompson, 1994; Smets et al., 1993), systemic lupus erythematosus (SLE) 
(Jacobson, Gange, Rose, & Graham, 1997), multiple sclerosis (Schwid, Covington, Segal, & Goodman, 
2002), Human Immunodeficiency Virus (HIV) infection, viral and cholestatic liver diseases, 
rheumatoid arthritis (Swain, 2000) and recently, it has been reported in patients with SCD as one of the 
major symptoms along with pain (While & Mullen, 2004), and thalassemia intermedia patients (Tabei 
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et al., 2013). Fatigue has been examined mostly in children’s populations (Panepinto et al., 2014; 
Dampier et al., 2016), as a symptom that affects quality of life in these patients (Dampier et al., 2010; 
Ameringer et al., 2014). 
However, understanding fatigue in chronic medical disease, remains difficult to prove and even though 
it is considered a primary or a common symptom, such as in multiple sclerosis or SLE, fatigue often 
does not correlate with disease status or physiological findings (Schwid et al., 2002; Krupp et al., 1990; 
Wang et al., 1998; Omdal et al., 2003). Even though, fatigue has been identified as a major symptom, 
affecting both health and quality of life in patients with sickle cell disease, and has been recognised as a 
major symptom affecting the quality of life in patients with thalassemia major as well (Lyrakos et al., 
2012), until now, there is no study exploring the factors affecting fatigue in patients with 
hemoglobinopathies under transfusion treatment, according to the biopsychosocial model of health.  
The purpose of the present study was to investigate the factors affecting the symptom of fatigue in 
patients with hemoglobinopathies under transfusion therapy, including both symptoms of the disease, 
as well as psychological factors and sociodemographic characteristics, according to the biopsychosocial 
model of health and illness.  
 
2. Method 
2.1 Participants 
This analysis included participants enrolled in a Thalassemia Transfusion Department at General 
Hospital of Nikaia “Ag. Panteleimon” (GHN), Greece, between 2016 and 2018. The study assessed 
common measures of fatigue, anxiety, depression and stress, hematological biomarkers, hemosiderosis 
level, chelation therapy, adherence to treatment and Health related quality of life (HRQoL) as well as 
socio-demographic characteristics in adult patients (>18 years) with hemoglobinopathies. The protocol 
was approved by the Hospital Scientific Board at General Hospital of Nikaia “Ag. Panteleimon” 
(G.H.N.). Written informed consent was obtained from all patients before their participation in the 
study. 
2.2 Measurements 
2.2.1 Multidimensional Fatigue Inventory (MFI) 
The MFI-20 comprises five subscales: general fatigue, physical fatigue, mental fatigue, reduced activity, 
and reduced motivation (Smets et al., 1995). Each subscale includes four items with five-point Likert 
scales. General fatigue includes general statements about fatigue and decreased functioning and was 
designed to encompass both physical and psychological aspects of fatigue. Physical fatigue concerns 
physical sensations related to fatigue. Mental fatigue pertains to cognitive functioning, including 
difficulty concentrating. Reduced activity refers to the influence of physical and psychological factors 
on the level of activity. Reduced motivation relates to lack of motivation for starting any activity. 
Scores on each subscale range from 4 to 20, with higher scores indicating greater fatigue. 
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2.2.2 Depression Anxiety Stress Scale 21 (DASS21) 
DASS-21 is a quantitative measure of distress on the basis of three subscales of depression, anxiety (eg, 
symptoms of psychological arousal), and stress (e.g., cognitive, subjective symptoms of anxiety) 
(Lovibond, P. F. & Lovibond, S. H., 1995). It is the short form of DASS 42 and it was used for this 
study because it is a measurement that has been validated in the Greek population and has been used in 
chronic patients as well (Lyrakos et al., 2011). Each subscale has 7 questions that respondents answered 
according to a Likert-type scale ranging between 0 (“does not apply to me at all”) to 3 (“applies to me 
very much, or most of the time”). 
2.2.3 Haematological Biomarkers  
Haemoglobin before transfusion and Serum ferritin concentration which is a useful but rather rough 
estimate of total body iron load, were measured the day of the interview. 
2.2.4 Magnetic Resonance Imaging 
Levels of T2* for heart and liver of the last five years were retrieved from patients files. This was 
decided because T2* imaging provides a precise quantification of myocardial and hepatic iron load and 
has become a useful tool for the evaluation of patients and for the therapeutic guidance and follow-up 
of iron chelation therapy (T2* reference values: normal, >25 ms; mild/moderate iron load, 8 to 20 ms; 
severe iron load, <8 ms) (Tanner et al., 2007). 
2.3 Statistical Analysis 
Statistical analysis was performed using programs available in the SPSS statistical package (SPSS 10.6, 
Chicago, USA). All variables were tested for normal distribution of the data. Data are shown as mean ± 
SD, unless it is stated otherwise. 
Univariate linear regression analysis was performed to look for the relationship between the total score 
of MFI and the five main domains of the inventory; General Fatigue, Physical Fatigue, Mental Fatigue, 
Reduced Activity and Reduced Motivation and the variables of interest in the sample population. Then, 
multivariate linear regression analyses were performed to look for independent associations between 
the five main domains of the MFI and the variables of interest, one for every domain of MFI (General 
Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity) and one for the 
total score of the inventory. The variables that were used in the models included the demographic 
characteristics of the sample (sex, age, education, marital status, place of residence), hematological 
biomarkers (hemoglobin and serum ferritin), magnetic reasoning markers (T2 * liver, T2 * heart), 
treatment variables like adherence to chelation treatment, frequency of transfusion per days, HRQoL as 
it was measured by the current health status, the kind of diagnosis, the type of chelation therapy, levels 
of anxiety, stress and depression, and qualitative characteristics of fatigue which included the cause of 
fatigue according to the patient, existence of fatigue before transfusion, and increase of fatigue during 
the last month. All independent variables in the multivariate analyses models were tested for 
multicolinearity. p<0.05 (two-tailed) was considered statistically significant. 
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3. Result 
The sample consisted of 63 females (61,4%) and 39 males (38,6%). The age of the sample ranged from 
19 to 72 years. The average age of the sample was 41.7 years with a standard deviation of 9.2 years, 
while the majority of participants were patients with a diagnosis of homozygous β-Thalassaemia (bT) 
(81.4%). Finally present health status had a mean of 69.9 with a SD 19.3, with minimum value 10 and 
maximum 100. The level of education, marital status, place of residence and diagnosis characteristics 
are presented in table 1, while means and standard deviations for fatigue, depression, anxiety, stress, 
hematological and magnetic reasoning markers are presented in Table 2 respectively.  
 
Table 1. Descriptive Summary Scores for the Demographic Characteristics of the Sample 
Variable  N % 
Sex  
Males  39 38.6 
Females  63 61.4 
Total  102 100 
Educational level (n=102) 
Primary school  13 12,9 
Elementary school 8 7,9 
High school  37 36,6 
University or college 40 39,6 
MSc- PhD 4 3,0 
Marital status (n=101)* 
Single  36 35,6 
Married  51 50,5 
Divorced  12 11,9 
Widow  2 2,0 
Place of residence (n=102)* 
Athens  84 84,0 
Rural area  16 16,0 
Diagnosis (n=102) 
Thalassemia major  78 76,5 
Thalassemia intermedia 17 16,7 
Sickle -beta Thalassemia 7 6,9 
N: number of participants; %: percent of total sample; 
*missing values are due to participants not answering the specific questions. 
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Table 2. Means and Standart Deviations of the Sample Variables 
 N Min Max M SD 
Age  102 27 72 44,73 9,59 
Hb 100 7,90 11,10 9,72 0,63 
Serum ferritin 100 20,70 10562 1539,82 1891,18 
T2 * liver 88 0,70 37,50 11,39 10,21 
T2 * heart 88 4,10 41,30 30,86 9,26 
Transfusion frequency 101 10 32 19,09 5,54 
Present health  100 10 95 66,42 19,56 
Depression 101 0 38 8,75 9,93 
Anxiety  100 0 40 6,26 7,02 
Stress  101 0 38 12,44 9,04 
General fatigue 100 4,00 20 12,14 3,22 
Physical fatigue  100 4,00 20 11,71 3,54 
Reduced activity  100 4,00 20 10,77 3,52 
Reduced motivation  100 4,00 17 9,85 3,12 
Mental fatigue  100 4,00 20 10,06 2,69 
M: Mean; SD: Std. Deviation; Min: Minimum; Max: Maximum. 
 
Sex, location, chelation treatment and existence of fatigue distribution were similar among the 
participants with thalassemia major, intermedia and sickle beta thalassemia (all comparisons were no 
significant). Significant differences were found in marital status between the 3 groups with the majority 
of thalassemia intermedia patients being marred (82.4%), while only 44,2% of thalassemia major 
patient were married. Age and transfusion frequency distribution had significant differences between 
participants (F=9.901, p=0.001 and F=38.938, p=0.001 respectively, while hemoglobin, ferritin, T2 * 
liver and T2 * heart distributions were similar among the participants with thalassemia major, 
intermedia and sickle beta thalassemia (all comparisons were non-significant) (Table 3).  
 
Table 3. Sample Distribution and Differences According to the Type of Hemoglobinopathy for the 
Independent Variables of Interest  
  
Thalassemia 
major 
Thalassemia 
intermedia 
Sickle-beta 
Thalassemia 
Test/p value 
Gender  Males 31 8 1 5.003*/0.082 
 Females 46 9 7  
Location  Athens  65 14 5 0.989*/0.610 
 Elsewhere  12 3 2  
Chelation  Deferoxamine  21 6 1 9.060*/0.170 
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 Deferasirox  15 5 3  
 Desferrioxamine 7 3 2  
 Combination** 34 3 2  
Existence of fatigue Yes  64 12 7 3.369*/0.184 
 No  14 5 0  
Age  (Mean/SD) 42.6±8.3a 50.5±9.7b 54.3±12.6c 
a-b-7.855/0.004 
a-c-11.670/0.003 
Hemoglobin  (Mean/SD) 9.8±0.5 9.5±0.6 9.3±1.2 F=3.065/0.051 
Ferritin  (Mean/SD) 1699.8±2086 963.1±911.4 1202.8±1891 F=1.178/0.312 
T2 * liver  (Mean/SD) 11.7±10.5 10.8±9.1 11.4±0.3 F=0.518/0.598 
T2 * heart (Mean/SD) 29.9±10.1 34.5±3.2 35.1±0.2 F=1.825/0.167 
Transfusion 
frequency per days 
(Mean/SD) 17.2±3.6a 23.7±6.6b 29.1±3.2c 
a-b-6.550/0.001 
a-c-11.987/0.001 
b-c-5.437/0.014 
*: chi square test or else F for ANOVA; ** Desferrioxamine & Deferoxamine; p value in bold if p<0.05; 
For ANOVA significant mean differences were calculated with the use of Bonferonni post hoc test. 
 
3.1 Multivariate Analysis  
The final model of multivariate analysis with the use of stepwise method using as dependent variable 
the total score of the MFI and independent variables sex, age, education, marital status, place of 
residence, hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of 
transfusion per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, 
depression, adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, 
and increase of fatigue in the last month is presented in Table 4. 
 
Table 4. Multifactorial Analysis with Dependent Variable Total Fatigue (Total Score of MFI) 
Final model with the independent variables contributing to the variance of the Total 
fatigue 
95,0% confidence 
intervals for B 
 B SE Beta t 
p 
value 
Lower 
bound 
Higher 
bound 
 
(Constant ) 62,426 4,312  14,477 0,000 53,843 71,009 
Health Thermometer -0,174 0,060 -0,290 -2,923 0,005 -0,292 -,056 
Fatigue before the transfussion< week 8,411 2,694 0,308 3,122 0,003 3,049 13,774 
Non adherence to chelation therapy 
after doctor’s orders 
4,969 2,359 0,209 2,106 0,038 0,273 9,665 
a. Dependent variable: Total fatigue; In bold statistical significant values for p<0.05. 
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Multivariate analysis showed that 23% of the variance in general fatigue (R2=0,231, p=0,038) is related 
with the current state of health as it is measured by the EQ-5D health thermometer (β=-0,290, p=0.005), 
existence of fatigue before transfusion for less than a week (β=-0.308, p=0.003) and non-adherence to 
chelation therapy for long periods of time following physician’s order (β=-0.209, p=0.038). 
The final model of multivariate analysis with the use of stepwise method using as dependent variable 
General fatigue and independent variables sex, age, education, marital status, place of residence, 
hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of transfusion 
per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, depression, 
adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, and increase 
of fatigue in the last month is presented in Table 5. 
 
Table 5. Multifactorial Analysis with Dependent Variable General Fatigue 
Final model with the independent variables contributing to the variance of the 
General Fatigue 
95,0% confidence 
intervals for B 
 B SE Beta t 
p 
value 
Lower 
bound 
Higher bound 
(Constant) 16,519 1,293  12,771 0,000 13,944 19,093 
Health Thermometer -0,060 0,018 -0,346 -3,330 0,001 -0,097 -0,024 
Subcutaneous chelator -2,390 1,009 -0,242 -2,369 0,020 -4,399 -0,382 
Fatigue from 2 weeks to 1 
month before transfusion  
-3,140 1,407 -0,233 -2,231 0,029 -5,941 -0,338 
a. Dependent variable: General fatigue; In bold statistical significant values for p<0.05. 
 
Multivariate analysis showed that 18% of the variance in General fatigue (R2=0,183, p=0,029) is 
related with the current state of health as measured by the EQ-5D health thermometer (β=-0.346, 
p=0.001), the use of subcutaneous chelation therapy (Desferrioxamine) (β=-0.242, p=0.02) and 
existence of fatigue before the transfusion for a period of two weeks to 1 month (β=-0.233, p=0.029). 
The final model of multivariate analysis with the use of stepwise method using as dependent variable 
Physical fatigue and independent variables sex, age, education, marital status, place of residence, 
hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of transfusion 
per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, depression, 
adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, and increase 
of fatigue in the last month is presented in Table 6. 
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Table 6. Multifactorial Analysis with Dependent Variable Physical Fatigue 
Final model with the independent variables contributing to the variance of the 
Physical fatigue 
95,0% confidence 
intervals for B 
 B SE Beta t 
p 
value 
Lower 
bound 
Higher 
bound 
(Constant) 16,064 1,373  11,703 0,000 13,331 18,797 
Health Thermometer -,077 ,019 -0,402 -4,042 0,000 -0,116 -,039 
Fatigue from 2 weeks to 1 month 
before transfusion 
-3,528 1,492 -0,237 -2,364 0,021 -6,499 -,557 
Combination chelation therapy  1,679 0,716 0,231 2,344 0,022 0,253 3,106 
Fatigue before transfusion< week 1,796 0,864 0205 2,080 0,041 0,077 3,516 
a. Dependent variable: General fatigue; In bold statistical significant values for p<0.05. 
 
Multivariate analysis showed that 26% of the variance in Physical fatigue (R2=0,266, p=0,04) is related 
to the current state of health as measured by the EQ-5D health thermometer (β=-0.402, p=0.001), 
existence of fatigue for a period of two weeks to one month before the transfusion (β=-0.237, p=0.021), 
use of combination chelation therapy (Desferrioxamine & Deferoxamine) (β=0.231, p=0.022) and 
existence of fatigue before transfusion for less than a week (β=0.205, p=0.041).  
The final model of multivariate analysis with the use of stepwise method using as dependent variable 
Reduced activity and independent variables sex, age, education, marital status, place of residence, 
hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of transfusion 
per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, depression, 
adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, and increase 
of fatigue in the last month is presented in Table 7. 
 
Table 7. Multifactorial Analysis with Dependent Variable Reduced Activity 
Final model with the independent variables contributing to the variance of Reduced 
activity 
95,0% confidence 
intervals for B 
 B SE Beta t 
p 
value 
Lower 
bound 
Higher 
bound 
(Constant) 8,740 0,510  17,150 0,000 7,726 9,755 
Fatigue before transfussion< week 2,833 0,844 0,330 3,356 0,001 1,153 4,514 
Sex 1,832 0,709 0,259 2,582 0,012 0,420 3,244 
Non adherence to chelation therapy 
after doctors’ orders 
1,652 0,748 0,221 2,208 0,030 0,163 3,140 
a. Dependent variable: General fatigue; In bold statistical significant values for p<0.05. 
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Multivariate analysis showed that 24% of the variance in reduced activity (R2=0.330, p=0.001) is 
related with existence of fatigue during the last days of the week before the transfusion (β=-0,330, 
p=0.005), gender and in particular being a woman (β=0.259, p=0.012) and non-adherence to chelation 
therapy for long periods of time following physician’s order (β=-0.221, p=0.030). 
The final model of multivariate analysis with the use of stepwise method using as dependent variable 
Reduced motivation and independent variables sex, age, education, marital status, place of residence, 
hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of transfusion 
per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, depression, 
adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, and increase 
of fatigue in the last month is presented in table 8. 
 
Table 8. Multifactorial Analysis with Dependent Variable Reduced Motivation 
Final model with the independent variables contributing to the variance of Reduced 
motivation 
95,0% confidence 
intervals for B 
 
B SE Beta t 
p 
value 
Lower 
bound 
Higher 
bound 
(Constant) 9,000 0,401  22,450 0,000 8,202 9,798 
Non adherence to chelation 
therapy after doctors’ orders 
2,115 0,708 0,313 2,990 0,004 ,707 3,524 
Fatigue due to working conditions 4,500 2,140 0,220 2,103 0,039 ,241 8,759 
a. Dependent variable: General fatigue; In bold statistical significant values for p<0.05. 
 
Multivariate analysis showed that 13% of the variance in reduced motivation (R2=0,132, p=0,039). Is 
related with non-adherence to chelation therapy for long periods of time following physician’s order 
(β=-0,313, p=0.004) and fatigue due to the working conditions of the patient (β=0.220, p=0.039). 
Finally, The final model of multivariate analysis with the use of stepwise method using as dependent 
variable Mental fatigue and independent variables sex, age, education, marital status, place of residence, 
hemoglobin, serum ferritin, T2 * liver, T2 * heart, ejection fraction of heart, frequency of transfusion 
per days, current health status, diagnosis, type of chelation therapy, anxiety, stress, depression, 
adherence to chelation treatment, cause of fatigue, existence of fatigue before transfusion, and increase 
of fatigue in the last month is presented in Table 9. 
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Table 9. Multifactorial Analysis with Dependent Variable Mental Fatigue 
Final model with the independent variables contributing to the variance of Mental 
fatigue 
95,0% confidence 
intervals for B 
 
B SE Beta t 
p 
value 
Lower 
bound 
Higher 
bound 
(Constant) 11,513 0,891  12,928 0,000 9,741 13,285 
Fatigue before transfussion < week 3,010 0,579 0,490 5,195 0,000 1,857 4,163 
Health Thermometer -,031 0,013 -0,231 -2,454 0,016 -0,057 -0,006 
a. Dependent variable: General fatigue; In bold statistical significant values for p<0.05. 
 
Multivariate analysis showed that 29% of the variance in mental fatigue (R2=0,290, p=0,016) is 
associated with existence of fatigue before transfusion for less than a week (β=0.490, p=0.001) and 
with the current state of health as it is measured by the health thermometer of the EQ-5D (β=-0.231, 
p=0.016). 
 
4. Discussion 
The aim of this study was to investigate the factors that explain the variance of fatigue through the 
biopsychosocial model for health and illness. The first result, regarding the type of hemoglobinopathy, 
was that there were no differences between thalassemia major, intermedia and sickle beta thalassemia 
patients in most of the variables, except the frequency between transfusions, which is a logical 
difference since every hemoglobinopathy has a different treatment pattern. The second difference was 
found in the mean age of the three groups, a result that has to do with the fact that both thalassemia 
intermedia as well as sickle beta thalassemia patients are starting transfusion therapy later in their life 
than thalassemia major patients.  
Regarding fatigue, analysis revealed that it was related with several variables, mostly physical. In fact 
every one of the five dimensions of MFI show a different model of correlations with mixed variables 
related with disease complications, adherence to treatment, sex, the self-perceived quality of life, as 
well as the qualitative characteristics of fatigue, something that leads us to a first conclusion that 
fatigue in hemoglobinopathies is multidimensional. 
As expected, our findings suggest that patients with hemoglobinopathies experiences fatigue, as it was 
measured with the MFI and different factors affect different dimension of fatigue.  
One of the major factors which had a significant effect in the total score of the questionnaire as well as 
in general and physical fatigue, was the health related quality of life, as it was measured with the 
thermometer of the EuroQ5D. This result is consistent with results of previous studies showing that 
fatigue is one of the factors affecting the quality of life in patients with hemoglobinopathies and vice 
versa (Dampier et al., 2010; Dampier et al., 2016; Ameringer, Elswick, & Smith, 2014; Lyon et al., 
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2014).  
Another important factor, which was revealed from the analysis, was the effect of adherence to 
chelation therapy and specifically, non-adherence to it for long periods of time, following physician’s 
order. This variable appeared to be one of the statistically significant independent variables in 
multifactorial regression models in more than one of the MFI scales and the present result comes to 
reinforce the results of previous studies, showing that noncompliance to chelation treatment is 
correlated with decreased quality of life in patients with hemoglobinopathies, since fatigue is one of the 
major factors that negatively affects HRQoL (Trachtenberg et al., 2011; Lurakos et al., 2012). 
Gender was also found to affect fatigue, with a higher percentage of women reporting fatigue than men. 
This result in relation to gender was expected, since it is not the first time that higher rates of fatigue in 
women have been found in patients with hemoglobinopathies (Dampier et al., 2016). Also, it has been 
found before that gender is one of the factors that affect the quality of life of patients with 
hemoglobinopathies (Sobota et al., 2011). 
As expected from previous reports, chelation therapy was one of the main factors that contributed to 
the regression models for fatigue. As we can see from the final models in the regression analysis, the 
use of combination chelation therapy (Desferrioxamine & Deferoxamine) had a positive effect in 
physical fatigue, which means that it correlates with reduced fatigue, while the use of subcutaneous 
chelation therapy (Desferrioxamine) had a negative effect in general fatigue and was correlated with 
increased fatigue. Our results supports the findings of other studies that different types of chelation 
therapy have a significant effect on health self-assessment, with patients receiving oral chelation 
therapy reporting better HRQoL (Lourenco et al., 2005) and is consistence with other studies that 
suggests that the quality of life of beta thalassemia major patients is dependent on type of iron chelation 
treatment which they received (Seyedifar et al., 2016; Karnon et al., 2008; Goulas, 
Kourakli-Symeonidis, & Camoutsis, 2012). Also, according to previous studies, patients receiving 
Desferrioxamine were more likely to suffer from fatigue, as well as depression, dyspnea, and decreased 
physical functioning (Abetz et al., 2006; Pakbaz et al., 2005) 
Another important factor explaining fatigue, seems to be the qualitative characteristics of fatigue, 
which was revealed from the opposite correlation, between the variables “existence of fatigue for a 
period between two weeks and a month” with “existing fatigue before transfusion for less than seven 
days”. This result regarding physical fatigue can be interpreted if we understand that the more recent 
the feeling of fatigue in the patients, the greater the level of fatigue they score in the inventories. 
Another interesting factor affecting reduced motivation was “fatigue due to working conditions”. This 
result though, was expected, since reduced motivation has to do with the patient’s inability to do things 
he used to do before, and work is an aggravating factor when fatigue coexists. This result supports 
previous findings in studies concerning patients with other chronic diseases, which found that when 
individuals suffers from fatigue as a result to working conditions, they score higher in the scales that 
evaluates fatigue (Weijman et al., 2004). 
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5. Conclusions  
In conclusion, as shown by all the models in multivariate analysis, the current self-evaluation off health, 
regarding physical health with its complications in people with hemoglobinopathies is the main factor 
affecting fatigue, noncompliance to chelation therapy is the second factor which is also known to be 
associated with hepatic and kidney hemosiderosis, higher serum ferritin values and reduced compliance 
to treatment, while chelation therapy is the third most important factor contributing negative to fatigue, 
as has been seen in previous studies as well (Porter et al., 2011; Tools & Therapy, 2013; Lyrakos et al., 
2011; Lyrakos et al., 2012).  
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